Contact dermatitis in patients undergoing serial intravitreal injections

Veramme, Jolien; Zaeytijd, Julie De; Lambert, Jo; Lapeere, Hilde

doi:10.1111/cod.12478

Cited by 19 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 16 ophthalmological patients undergoing repeated intravitreal injections with anti-VEGF contact dermatitis had developed in the Ghent department; 9 patients reacted to phenylephrine, 5 to iso-Betadine ® ophthalmic solution and 3 patients to sodium metabisulfite [ 153 ]. Betadine ® is a brand name for povidone iodine-containing solutions.…”

Section: Resultsmentioning

confidence: 99%

Contact Allergy: A Review of Current Problems from a Clinical Perspective

Uter

Werfel

White

et al. 2018

IJERPH

View full text Add to dashboard Cite

Contact allergy is common, affecting 27% of the general population in Europe. Original publications, including case reports, published since 2016 (inclusive) were identified with the aim of collating a full review of current problems in the field. To this end, a literature search employing methods of systematic reviewing was performed in the Medline® and Web of Science™ databases on 28 January 2018, using the search terms (“contact sensitization” or “contact allergy”). Of 446 non-duplicate publications identified by above search, 147 were excluded based on scrutiny of title, abstract and key words. Of the remaining 299 examined in full text, 291 were deemed appropriate for inclusion, and main findings were summarised in topic sections. In conclusion, diverse sources of exposures to chemicals of widely-differing types and structures, continue to induce sensitisation in man and may result in allergic contact dermatitis. Many of the chemicals are “evergreen” but others are “newcomers”. Vigilance and proper investigation (patch testing) are required to detect and inform of the presence of these haptens to which our populations remain exposed.

show abstract

Section: Resultsmentioning

confidence: 99%

Contact Allergy: A Review of Current Problems from a Clinical Perspective

Uter

Werfel

White

et al. 2018

IJERPH

View full text Add to dashboard Cite

show abstract

“…Approximately 90% of the uveitis and iritis cases were mild to moderate, and were treated with a course of topical corticosteroids or antibiotics, and most resolved with no sequelae [ 8 ]. Hypersensitivity reactions after anti-VEGF therapy mostly involve type I hypersensitivity reactions due to substances used during intravitreal injection [ 9 ]. In our case, 1 day after the second injection, flares and 2 + cells were observed in the anterior chamber.…”

Section: Discussionmentioning

confidence: 99%

Choroidal Effusion following Intravitreal Brolucizumab Injection: A Case Report

Sim¹,

Kim²,

Hwang³

2022

Case Rep Ophthalmol

View full text Add to dashboard Cite

This report describes a case of choroidal effusion after intravitreal brolucizumab injection for wet age-related macular degeneration (AMD). A 71-year-old Korean man with a history of wet AMD visited our clinic. On examination, the best-corrected distance visual acuity (BCVA) was 20/200 in the right eye. Fundus photography and optical coherence tomography showed wet AMD in the right eye. The patient showed no improvement while undergoing treatment with anti-vascular endothelial growth factor therapy (aflibercept, 6 times; ranibizumab, 5 times; and bevacizumab 3 times). We administered intravitreal brolucizumab injections in the right eye of the patient. After first brolucizumab injection, the BCVA improved from 20/200 to 20/63 in the right eye. Two months after the intravitreal brolucizumab injection, recurrence of wet AMD and deterioration of the BCVA to 20/200 was observed on the right eye. The patient underwent a second intravitreal brolucizumab injection in the right eye in the same manner. Three days after the second brolucizumab injection, choroidal effusion was observed in the right eye. The choroidal effusion resolved completely 12 days after the injection, without any additional treatment. Intravitreal brolucizumab injection may provoke choroidal effusion. Although it may resolve promptly, short-term follow-up fundus examinations may be necessary for the early diagnosis and treatment of this complication.

show abstract

“…It is important to identify the causative agent and the pharmacologically related agents (with which there can be cross-sensitization), so that the susceptible patient can avoid preparations containing them in the future. Viramme et al has studied sixteen cases of EACD after intravitreal injections and have been published [5]. The allergens were phenylephrine (9/16), isobetadine ophthalmic solution (5/16) and sodium metabisulfite (3/16), and none of these were directly related to anti intravitreal injections -VEGF.…”

Section: Discussionmentioning

confidence: 99%